Immunotherapy Stocks List

Immunotherapy Stocks Recent News

Date Stock Title
Apr 30 INMB INmune Bio provides update on Alzheimer's candidate XPro
Apr 30 INMB INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years
Apr 30 IBRX ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association
Apr 29 IBRX Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Apr 29 IBRX Tesla, Deciphera Pharmaceuticals, Heartland Financial And Other Big Stocks Moving Higher On Monday
Apr 29 INMB INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
Apr 29 IBRX Why Philips Shares Are Trading Higher By 37%; Here Are 20 Stocks Moving Premarket
Apr 26 INMB INmune Bio Independent Director Acquires 80% More Stock
Apr 25 LAB Standard Biotools announces operational restructuring plan including headcount reduction
Apr 25 INMB INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Apr 25 FBIOP Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024
Apr 25 LAB Standard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth
Apr 25 CADL Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
Apr 25 LAB Standard BioTools Announces Conference Call and Webcast for First Quarter 2024 Financial Results on May 8, 2024
Apr 25 IBRX ImmunityBio immunotherapy shows positive overall survival in lung cancer trial
Apr 25 IBRX Why Teradyne Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
Immunotherapy

Immunotherapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies.

In recent years, immunotherapy has become of great interest to researchers, clinicians and pharmaceutical companies, particularly in its promise to treat various forms of cancer.Immunomodulatory regimens often have fewer side effects than existing drugs, including less potential for creating resistance when treating microbial disease.Cell-based immunotherapies are effective for some cancers. Immune effector cells such as lymphocytes, macrophages, dendritic cells, natural killer cells (NK Cell), cytotoxic T lymphocytes (CTL), etc., work together to defend the body against cancer by targeting abnormal antigens expressed on the surface of tumor cells.
Therapies such as granulocyte colony-stimulating factor (G-CSF), interferons, imiquimod and cellular membrane fractions from bacteria are licensed for medical use. Others including IL-2, IL-7, IL-12, various chemokines, synthetic cytosine phosphate-guanosine (CpG) oligodeoxynucleotides and glucans are involved in clinical and preclinical studies.

Browse All Tags